维尔生物技术公司超过了预期的收益,宣布了关键合作,并筹集了1.5亿美元,但内部销售导致其股价在2026年2月26日下跌至9.32美元. Vir Biotechnology beat earnings estimates, announced a key collaboration, and raised $150M, but insider sales caused its stock to drop to $9.32 on February 26, 2026.

2026年2月23日,Vir生物技术公司报告季度成果强劲,收入为6 407万美元,远高于1 991万美元的估计数,每股损失0.31美元,比预期高出11美元。 On February 23, 2026, Vir Biotechnology reported strong quarterly results, with revenue of $64.07 million—well above the $19.91 million estimate—and a loss of $0.31 per share, beating expectations by $0.11. 该公司宣布与Astallas就VIR-5500方案开展全球合作,并辅之以积极的第一阶段数据,并通过公开募捐筹集了1.5亿美元。 The company announced a global collaboration with Astellas on the VIR-5500 program, supported by positive Phase 1 data, and raised $150 million through a public offering. 尽管分析师的升级和协商一致的“机动购买”评级,但包括CEO和CFO在内的多个内部人员在2月23日至25日期间出售股票,导致2月26日股票跌至9.32美元,降为0.68美元,数额很大。 Despite analyst upgrades and a consensus “Moderate Buy” rating, multiple insiders, including the CEO and CFO, sold shares between February 23 and 25, contributing to a stock decline to $9.32 on February 26, down $0.68 with high volume. 该公司以免疫学和传染病治疗为重点,市场上限为13亿美元。 The company, focused on immunology and infectious disease therapies, has a market cap of $1.3 billion.